Supplemental material - U Okata-Karigane et al., 2022

Published: 2 September 2022| Version 1 | DOI: 10.17632/brjdyhcrwf.1
Utako Karigane


Supplemental Material related to "Phase 2 randomized controlled trial of serlopitant, a neurokinin 1 receptor antagonist for chronic pruritus in epidermolysis bullosa. U Okata-Karigane et al., 2022" Supplemental Figure S1. Participant flow Supplemental Figure S2. Weekly mean NRS scores stratified by treatment groups for Worst Itch NRS Supplemental Table S1. Additional eligible criteria Supplemental Table S2. Minimal Clinically Important Difference (MCID) for the Average Itch NRS at month2 Supplemental Table S3. The change in the static participant assessment of itch on a 5-point categorical scale at month 2



Epidermolysis bullosa, Controlled Clinical Trial, Neurokinin Receptor Antagonist, Pruritus